Hey all, welcome back to the real life pharmacology podcast. I'm your host, pharmacist, Eric Christensen.

Thank you so much for listening today. As always, go check out the free 31-page PDF on the top 200 drugs.

Great study guide, great refresher, lots of things on there that will show up on board exams as well as in clinical practice.

So simply an email, we'll get you access to that, absolutely no-brainer. of things on there that will show up on board exams as well as in clinical practice. So

simply an email, we'll get you access to that. Absolutely no-brainer to go ahead and get that

at real-life pharmacology.com. All right, so we are going to be talking anti-arithmics today.

This is generally considered a class of higher risk medications.

Keep in mind, there's some different classes and some different agents, and we've got things like,

you know, beta blockers and calcium channel blockers, which maybe aren't classified as more

higher risk medications, but many of the others within this

class of drug are considered a little bit more high risk. Some other things that I just wanted

to kind of give you a general outline on, a review, if you will, narrow therapeutic index

medications. So a lot of antirthymics or some of them

certainly have this concern. So basically what that means is it's a tight window between a toxic

concentration and a subtherapeutic concentration. So sometimes it can be difficult to get

the dosing just right to where we effectively treat the condition, the arrhythmia, if you will,

but also avoid toxicity. So that's harder to do when we've got a narrow therapeutic index medication.

And also, whenever you have a narrow therapeutic index medication,

you're often going to be checking lab work to make sure that that medication stays within the target concentration that we're

trying to do.

So again, many antirhythics do fall within this window.

The classic, classic examples that show up on board exams and, you know, you may see out in practice are one amyodorone and two

...